Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 12, 2002

View Archived Issues

Cyclis licenses broad technology to expand ACT platform

Immunomedics' unlabeled CEA antibody inhibits tumor growth and enhances dacarbazine therapy

APT-3111 awarded E.U. orphan drug status for paroxysmal nocturnal hemoglobinuria

New modulators of adenosine receptors identified at Bayer

Japanese patent covers novel alpha2-adrenoceptor antagonists designed by Fuso scientists

Several related series of guanylate cyclase activators described by Bayer

New antitumor hydroxamates prepared and tested at Ono

Ono scientists design novel chemokine antagonists for asthma, arthritis, etc.

Tropane analogue RTI-336 as a potential therapeutic for cocaine abuse

New mu/delta opioid receptor agonist under study for the management of GI motility disorders

Beneficial effects for NCX-1000 in animal model of cholangitis

Major active component of TJ-135 determined using hepatic stellate cells

Data supporting ongoing clinical development of ACH-126443 for HBV presented at meetings

Effect of emerging precore stop codon mutation on anti-HBV activity of LY-582563/MCC-478

Antitumor activity of TRAIL-R1 MAb demonstrated in vitro and in vivo

Preclinical data reported for Ono-2506 at Neuroscience 2002

OraQuick rapid HIV-1 test approved

Inflazyme announces phase Ia and Ib results with IPL-512602

ENMD-0995 receives orphan drug designation

Aphton initiates clinical trials with G17DT for GERD in Europe

Pay now or pay later: new report sheds light on the economic impact of osteoporosis in the workplace

Inspire announces phase II results with INS-37217

Top-line results of phase III study of alvimopan in opioid bowel dysfunction

Evidence supporting the use of neurokinin receptor antagonists in depression

FDA designates Orathecin as a fast track drug

HuMax-CD4 to be tested in cancer patients

Cetirizine approved for pediatric use

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...